Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 2/3 1

Status

Completed 3Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 3Sarcoma 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 21Neoplasms 6Carcinoma, Hepatocellular 5Stomach Neoplasms 4Recurrence 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Advanced Cancer 4Uveal Melanoma 3Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Liver Neoplasms 3Colonic Neoplasms 3Rectal Neoplasms 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasm Metastasis 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Hodgkin Disease 2Hematologic Neoplasms 2Glioma 2Glioblastoma 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Basal Cell 2Brain Neoplasms 2

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Neoplasms × relatlimab × Clear all
NCT03899155 2026-05-27

Pan Tumor Rollover Study

Bristol-Myers Squibb

Phase 2 Recruiting
1,500 enrolled
Tumor-Agnostic

Neoplasms

NCT04095208 2026-04-21

CONGRATS

Institut Bergonié

Phase 2 Completed
68 enrolled
Sarcoma

Tertiary Lymphoid Structures, Neoplasm Metastasis, Neoplasms, Sarcoma

NCT03470922 2025-09-09

RELATIVITY-047

Bristol-Myers Squibb

Phase 2/3 Active not recruiting
714 enrolled 17 charts 1 FDA
Dermatologic

Melanoma, Neoplasms

NCT06237920 2025-09-03

TURANDORELA

The Netherlands Cancer Institute

Phase 2 Recruiting
90 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Female Urogenital Diseases and Pregnancy Complications, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT02966548 2025-02-17

Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1 Completed
35 enrolled
Tumor-Agnostic

Neoplasms

NCT04112498 2023-04-06

A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab

Bristol-Myers Squibb

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡